Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related postsSubcutaneous Daratumumab Plus CyBorD Improves Outcomes in AL AmyloidosisJuly 2, 20202023 Fall NewsletterOctober 12, 20232022 Summer NewsletterJuly 14, 2022 Previous post2026 Winter NewsletterNext postCARES Phase III clinical program did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosis
